DiogenX Stock

DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.

Sign up today and learn more about DiogenX Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About DiogenX Stock

DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.

Funding History

June 2020$4.5M
May 2023$27.5M

Management

Board Member

Johannes Zanzinger

Board Member

David Evans

Board Member

Matthieu Coutet

Co-Founder

Patrick Collombat

Board Member

Katie Ellias

Co-founder

Jean-Pascal Tranié

Chief Executive Officer - Co-founder

Benjamin Charles

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo